MacroGenics (MGNX) Competitors $1.58 +0.09 (+6.04%) Closing price 04:00 PM EasternExtended Trading$1.58 -0.01 (-0.32%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MGNX vs. PRTA, AUTL, KMDA, VERV, ORKA, RVNC, SANA, FULC, ABVX, and RAPPShould you be buying MacroGenics stock or one of its competitors? The main competitors of MacroGenics include Prothena (PRTA), Autolus Therapeutics (AUTL), Kamada (KMDA), Verve Therapeutics (VERV), Oruka Therapeutics (ORKA), Revance Therapeutics (RVNC), Sana Biotechnology (SANA), Fulcrum Therapeutics (FULC), ABIVAX Société Anonyme (ABVX), and Rapport Therapeutics (RAPP). These companies are all part of the "pharmaceutical products" industry. MacroGenics vs. Prothena Autolus Therapeutics Kamada Verve Therapeutics Oruka Therapeutics Revance Therapeutics Sana Biotechnology Fulcrum Therapeutics ABIVAX Société Anonyme Rapport Therapeutics MacroGenics (NASDAQ:MGNX) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, profitability, community ranking, risk, earnings and dividends. Do insiders & institutionals have more ownership in MGNX or PRTA? 96.9% of MacroGenics shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 13.0% of MacroGenics shares are owned by insiders. Comparatively, 9.2% of Prothena shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media prefer MGNX or PRTA? In the previous week, MacroGenics had 4 more articles in the media than Prothena. MarketBeat recorded 11 mentions for MacroGenics and 7 mentions for Prothena. Prothena's average media sentiment score of 1.30 beat MacroGenics' score of 0.17 indicating that Prothena is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MacroGenics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Prothena 4 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer MGNX or PRTA? Prothena received 189 more outperform votes than MacroGenics when rated by MarketBeat users. Likewise, 70.56% of users gave Prothena an outperform vote while only 61.88% of users gave MacroGenics an outperform vote. CompanyUnderperformOutperformMacroGenicsOutperform Votes42761.88% Underperform Votes26338.12% ProthenaOutperform Votes61670.56% Underperform Votes25729.44% Is MGNX or PRTA more profitable? MacroGenics has a net margin of -69.07% compared to Prothena's net margin of -90.50%. Prothena's return on equity of -22.67% beat MacroGenics' return on equity.Company Net Margins Return on Equity Return on Assets MacroGenics-69.07% -89.42% -38.57% Prothena -90.50%-22.67%-19.68% Which has more risk & volatility, MGNX or PRTA? MacroGenics has a beta of 2.2, suggesting that its share price is 120% more volatile than the S&P 500. Comparatively, Prothena has a beta of 0.11, suggesting that its share price is 89% less volatile than the S&P 500. Which has higher valuation & earnings, MGNX or PRTA? MacroGenics has higher revenue and earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than MacroGenics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMacroGenics$152.43M0.65-$9.06M-$0.89-1.78Prothena$137.94M2.56-$147.03M-$2.08-3.15 Do analysts prefer MGNX or PRTA? MacroGenics presently has a consensus price target of $6.13, suggesting a potential upside of 287.66%. Prothena has a consensus price target of $51.71, suggesting a potential upside of 689.53%. Given Prothena's stronger consensus rating and higher possible upside, analysts clearly believe Prothena is more favorable than MacroGenics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MacroGenics 0 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.40Prothena 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88 SummaryProthena beats MacroGenics on 10 of the 18 factors compared between the two stocks. Get MacroGenics News Delivered to You Automatically Sign up to receive the latest news and ratings for MGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGNX vs. The Competition Export to ExcelMetricMacroGenicsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$99.68M$6.48B$5.33B$8.39BDividend YieldN/A2.64%5.21%4.11%P/E Ratio-1.009.0626.7119.71Price / Sales0.65251.50386.13120.55Price / CashN/A65.8538.2534.62Price / Book0.646.456.774.50Net Income-$9.06M$143.98M$3.23B$248.22M7 Day Performance2.60%2.41%1.80%0.56%1 Month Performance3.95%4.56%11.10%13.17%1 Year Performance-66.38%-2.67%17.11%7.30% MacroGenics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGNXMacroGenics3.6839 of 5 stars$1.58+6.0%$6.13+287.7%-65.0%$99.68M$152.43M-1.00430News CoverageAnalyst ForecastAnalyst RevisionPRTAProthena3.855 of 5 stars$7.40+3.1%$51.71+598.8%-68.5%$398.32M$137.94M-3.22130Positive NewsAUTLAutolus Therapeutics3.096 of 5 stars$1.48+11.3%$9.32+529.7%-62.0%$393.89M$9.01M-1.22330High Trading VolumeKMDAKamada3.9227 of 5 stars$6.82-1.7%$14.67+115.1%+28.9%$392.01M$160.95M24.36360Analyst UpgradeAnalyst RevisionVERVVerve Therapeutics3.513 of 5 stars$4.37-5.6%$25.75+489.2%-23.6%$389.56M$59.61M-1.78110Trending NewsAnalyst UpgradeAnalyst RevisionORKAOruka Therapeutics2.3453 of 5 stars$10.31+2.5%$39.86+286.6%N/A$386.02MN/A-1.65N/ANews CoverageAnalyst ForecastAnalyst RevisionGap UpRVNCRevance Therapeutics2.5932 of 5 stars$3.65flat$8.45+131.5%N/A$381.02M$234.04M-1.89500News CoverageAnalyst ForecastSANASana Biotechnology2.43 of 5 stars$1.68-3.7%$10.80+542.9%-76.4%$378.80MN/A-1.20380Gap DownFULCFulcrum Therapeutics0.7835 of 5 stars$6.93+0.7%$4.50-35.1%-18.2%$374.07M$80M-22.35100ABVXABIVAX Société Anonyme2.4466 of 5 stars$5.88-2.2%$34.00+478.2%-59.3%$372.90MN/A0.0061RAPPRapport Therapeutics1.5228 of 5 stars$10.19+2.3%$32.67+220.6%N/A$371.92MN/A-2.95N/A Related Companies and Tools Related Companies Prothena Alternatives Autolus Therapeutics Alternatives Kamada Alternatives Verve Therapeutics Alternatives Oruka Therapeutics Alternatives Revance Therapeutics Alternatives Sana Biotechnology Alternatives Fulcrum Therapeutics Alternatives ABIVAX Société Anonyme Alternatives Rapport Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGNX) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MacroGenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MacroGenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
